COVID-19

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…

8 months ago

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel…

8 months ago

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

8 months ago

Entourage Health Reports Fiscal Year 2023 Financial Results and Posts $54 Million in Total Revenues

Strategic Cost Management Signals Stronger Financial Health and Future StabilityGross profit before fair value changes reached $2.4 million, reflecting a…

8 months ago

HD Nursing Honored as Silver Stevie® Award Winner in 2024 American Business Awards®

BENTON, Ark.--(BUSINESS WIRE)--HD Nursing, the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention,…

9 months ago

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:…

9 months ago

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for…

9 months ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,…

9 months ago

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events

Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage…

9 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

- Top-line Results Expected in the Second Half of 2024 -PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics,…

9 months ago